Published in AIDS on April 01, 1997
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother (1999) 2.08
Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates. Antimicrob Agents Chemother (2000) 1.49
ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2002) 1.23
Antiretroviral Drug Resistance in HIV-1. Curr Infect Dis Rep (1999) 0.87
Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med (1992) 8.15
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. N Engl J Med (1993) 4.88
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS (1999) 4.39
A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med (1995) 3.04
Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. J Viral Hepat (2009) 3.02
Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis (1990) 2.83
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. JAMA (1994) 2.56
[CD4+ lymphocytes and opportunistic infections and neoplasms in patients with human immunodeficiency virus infection]. Med Clin (Barc) (1994) 2.56
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med (2000) 2.49
European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis (2011) 2.47
Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill (2008) 2.43
Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother (2001) 2.42
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect (2011) 2.38
Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood (2001) 2.37
Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. Am J Med (1996) 2.36
Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med (1996) 2.22
Adenosine deaminase in pleural fluids. Test for diagnosis of tuberculous pleural effusion. Chest (1983) 2.15
Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1995) 2.14
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS (1996) 2.14
Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect (2009) 2.13
Re-intubation increases the risk of nosocomial pneumonia in patients needing mechanical ventilation. Am J Respir Crit Care Med (1995) 2.07
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob Agents Chemother (2007) 2.04
[Antimicrobial therapy in exacerbated chronic obstructive pulmonary disease]. Arch Bronconeumol (2002) 2.03
Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS (1999) 2.00
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother (2002) 2.00
Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) (2001) 2.00
Visceral leishmaniasis in immunocompromised hosts. Am J Med (1987) 1.99
Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses (2008) 1.98
[Treatment and prophylaxis of the principal infections associated with the human immunodeficiency virus]. Med Clin (Barc) (1993) 1.96
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS (2001) 1.92
HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS (2001) 1.90
Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis (2008) 1.86
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med (2008) 1.84
The expression of neurogenic loci in imaginal epidermal cells of Drosophila melanogaster. J Neurogenet (1984) 1.83
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol (2001) 1.83
Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV). Ann Intern Med (1989) 1.82
Gastrointestinal leishmaniasis in human immunodeficiency virus-infected patients: report of five cases and review. Clin Infect Dis (1994) 1.82
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS (2001) 1.81
Evaluation of a new system, VITEK 2, for identification and antimicrobial susceptibility testing of enterococci. J Clin Microbiol (2000) 1.78
Evolution of susceptibilities of Campylobacter spp. to quinolones and macrolides. Antimicrob Agents Chemother (1994) 1.78
Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS (1999) 1.73
Multiply antibiotic-resistant Streptococcus pneumoniae recovered from Spanish hospitals (1988-1994): novel major clones of serotypes 14, 19F and 15F. Microbiology (1996) 1.69
Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med (1993) 1.69
Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS (2000) 1.67
Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother (2007) 1.66
Functional interactions of neurogenic genes of Drosophila melanogaster. Genetics (1988) 1.65
Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest (1988) 1.64
Evaluation of the upgraded amplified Mycobacterium tuberculosis direct test (gen-probe) for direct detection of Mycobacterium tuberculosis in respiratory and non-respiratory specimens. Diagn Microbiol Infect Dis (2001) 1.60
The influence of intravenous drug use and HIV infection in the transmission of tuberculosis. AIDS (1996) 1.60
Evaluation of the MB/BacT mycobacterium detection system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol (2000) 1.59
Failure of ciprofloxacin therapy for invasive nontyphoidal salmonellosis. Clin Infect Dis (1998) 1.59
Introduction of HIV drug-resistance testing in clinical practice. AIDS (1999) 1.58
Klebsiella bacteremia: an analysis of 100 episodes. Rev Infect Dis (1985) 1.56
Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS (2001) 1.56
Thalidomide in patients with acquired immunodeficiency syndrome. Arch Intern Med (1992) 1.56
Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet (2001) 1.55
Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Respir Crit Care Med (2000) 1.55
Bloodstream infections in patients with kidney disease: risk factors for poor outcome and mortality. J Hosp Infect (2013) 1.55
Yersinia enterocolitica Septicemia. Am J Clin Pathol (1980) 1.54
EGF homologous sequences encoded in the genome of Drosophila melanogaster, and their relation to neurogenic genes. EMBO J (1987) 1.52
Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS. J Infect (1990) 1.50
Comparison of three commercial methods for rapid detection of Clostridium difficile toxins A and B from fecal specimens. J Clin Microbiol (2008) 1.49
Component-resolved diagnosis of vespid venom-allergic individuals: phospholipases and antigen 5s are necessary to identify Vespula or Polistes sensitization. Allergy (2012) 1.48
Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group. Ann Intern Med (1995) 1.47
Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: an international study. Br J Haematol (1997) 1.47
The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS (2001) 1.46
CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc Natl Acad Sci U S A (2005) 1.45
Multicenter evaluation of the NucliSens EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma. J Virol Methods (2005) 1.45
High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response. J Acquir Immune Defic Syndr (1999) 1.44
[Strongyloidiasis and HTLV-I infection]. Med Clin (Barc) (1999) 1.44
Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping. AIDS Res Hum Retroviruses (1996) 1.42
HIV-1 and HIV-2 infections in a high-risk population in Bombay, India: evidence for the spread of HIV-2 and presence of a divergent HIV-1 subtype. J Acquir Immune Defic Syndr (1992) 1.42
Candida infective endocarditis. Eur J Clin Microbiol Infect Dis (2008) 1.41
Survival differences in European patients with AIDS, 1979-89. The AIDS in Europe Study Group. BMJ (1994) 1.41
[Interferon in chronic hepatitis in patients infected by the human immunodeficiency virus: yes or no?]. Med Clin (Barc) (1992) 1.40
[Cytokines value as a sepsis and mortality predictor in elderly patients with fever]. Med Clin (Barc) (2003) 1.40
Adenosine deaminase activity in the diagnosis of tuberculous peritonitis. Gut (1986) 1.40
Direct cost of management and treatment of active systemic lupus erythematosus and its flares in Spain: the LUCIE Study. Rev Clin Esp (Barc) (2013) 1.40
[Clinical and epidemiological characteristics of persons newly diagnosed of HIV infection]. Med Clin (Barc) (2001) 1.40
[Oral leishmaniasis in a patient with the human immunodeficiency virus]. Med Clin (Barc) (1994) 1.40
[Usefulness of the somatostatin analog SMS 201-995 in the treatment of diarrhea in patients infected with the human immunodeficiency virus]. Med Clin (Barc) (1990) 1.40
Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 1.40
Molecular cloning of two west African human immunodeficiency virus type 2 isolates that replicate well in macrophages: a Gambian isolate, from a patient with neurologic acquired immunodeficiency syndrome, and a highly divergent Ghanian isolate. Proc Natl Acad Sci U S A (1989) 1.40
Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J (2000) 1.40
[An esophageal ulcer due to cytomegalovirus in a female patient infected with the human immunodeficiency virus without serious immunosuppression: is this an acquired immunodeficiency syndrome?]. Med Clin (Barc) (1992) 1.40